Theralase targets up to C$5 million in brokered private placement at C$0.24 per unit
Reuters2026/08/10 21:16- Theralase launched a brokered LIFE private placement of units at C$ 0.24 to raise C$ 3 million to C$ 5 million.
- Each unit includes 1 common share, 1 warrant exercisable at C$ 0.32 until May 20, 2031.
- Proceeds earmarked for GLP toxicology work supporting clinical development of Rutherrin intravenous cancer program, Ruvidar topical cold sore program, working capital.
- Research Capital to act as sole agent; offering size can increase by up to 15% via an over-allotment option.
- Closing targeted for Aug. 24, 2026, subject to TSXV approval.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Telstra announces annual shareholder meeting notice
TEL Venture Capital invests in Japan’s Advance Composite
AI success leads to deflation, failure shifts focus to safety! Apollo Chief Economist: Regardless of the scenario, U.S. Treasury yields will decline in 2027.
Torsten Slok believes that successful AI commercialization will lead to a large-scale deflationary effect, resulting in declining interest rates; if the AI bubble bursts, the Nasdaq could plummet by 50%, prompting a surge of safe-haven funds into US Treasuries and causing yields to drop sharply as well. The next six months are a key window; market narratives are expected to shift from "inflation + fiscal deficit" to the success or failure of AI. Current high interest rates may be on the eve of a turning point.
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
